Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China flag China · Delayed Price · Currency is CNY
6.15
-0.21 (-3.30%)
Nov 13, 2026, 3:04 PM CST

SHE:002550 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
602.15491.05439.95576.23409.26617.81
Short-Term Investments
-76.2192.964.95--
Trading Asset Securities
663.86594.02273.8371.9867.4868.23
Cash & Short-Term Investments
1,2661,161906.67713.16476.73686.03
Cash Growth
20.60%28.08%27.13%49.59%-30.51%-8.58%
Accounts Receivable
239.26299.1274.25275.52632.87447.67
Other Receivables
21.0118.9423.2416.92.482.56
Receivables
260.27318.04297.48292.42635.35450.23
Inventory
414.37372.44426.81602.01536.48400.63
Prepaid Expenses
-----0.01
Other Current Assets
156.0556.6762.7318.3938.7233.04
Total Current Assets
2,0971,9081,6941,6261,6871,570
Property, Plant & Equipment
697.08681.93563.6561.27616.39611.77
Long-Term Investments
51.14134.16160.08203.22156.7840.56
Goodwill
11.1411.1411.1411.1411.1411.14
Other Intangible Assets
104.72107.21109.32113.14100.86106.92
Long-Term Deferred Tax Assets
70.7666.5275.2690.53101.4999.42
Long-Term Deferred Charges
200.16173.03138.0493.7760.3346.85
Other Long-Term Assets
6.834.4715.33.0571.6721.81
Total Assets
3,2393,0872,8302,7662,8062,508

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
74.6277.5188.6441.1845.9771.23
Accrued Expenses
47.68125.688.0689.7101.9499.55
Short-Term Debt
75.550.2721.4956.31103.0593.56
Current Income Taxes Payable
-0.441.530.640.05-
Current Unearned Revenue
5.77.649.689.7115.5819.67
Other Current Liabilities
150.0712.75148.2811.6312.34
Total Current Liabilities
353.63224.21223.39205.81278.22296.35
Long-Term Leases
3.143.07----
Long-Term Unearned Revenue
92.7888.5886.4681.8589.3593.42
Long-Term Deferred Tax Liabilities
4.644.784.024.524.960.47
Total Liabilities
454.19320.64313.87292.17372.53390.24

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,2801,2801,2801,2801,2801,280
Additional Paid-In Capital
38.5441.4241.6541.6536.2929.38
Retained Earnings
1,6441,6181,3691,1631,134960.89
Treasury Stock
-156.88-170.86-170.86-30.09--145.05
Comprehensive Income & Other
-0.8-0.55-2.420.36-0.062.23
Total Common Equity
2,8052,7682,5172,4552,4502,127
Minority Interest
-20.29-1.68-0.8718.98-16.95-9.09
Shareholders' Equity
2,7842,7662,5172,4742,4332,118
Total Liabilities & Equity
3,2393,0872,8302,7662,8062,508

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
78.693.3421.4956.31103.0593.56
Net Cash (Debt)
1,1871,158885.19656.85373.69592.48
Net Cash Growth
13.11%30.81%34.76%75.78%-36.93%-16.38%
Net Cash Per Share
0.950.930.700.510.290.49
Filing Date Shares Outstanding
1,2611,2501,2501,2751,2801,280
Total Common Shares Outstanding
1,2611,2501,2501,2751,2801,280
Working Capital
1,7431,6841,4701,4201,4091,274
Book Value Per Share
2.222.212.011.931.911.66
Tangible Book Value
2,6892,6502,3972,3312,3382,009
Tangible Book Value Per Share
2.132.121.921.831.831.57
Buildings
-568.23498.75498.75525.73524.28
Machinery
-624.66568.44558.3504.84461.29
Construction In Progress
-110.3961.258.1954.139.24